Amylyx Pharmaceuticals
AMLX
143 hedge funds and large institutions have $141M invested in Amylyx Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 56 increasing their positions, 48 reducing their positions, and 60 closing their positions.
94% more call options, than puts
Call options by funds: $20.5M | Put options by funds: $10.6M
17% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 48
20% less funds holding
Funds holding: 178 → 143 (-35)
20.41% less ownership
Funds ownership: 93.47% → 73.06% (-20%)
58% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 60
85% less capital invested
Capital invested by funds: $929M → $141M (-$788M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$22.1M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$19.6M |
| 3 |
Two Sigma Investments
New York
|
+$18.2M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$47M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$43.6M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$36.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$33.8M |
| 5 |
PA
Perceptive Advisors
New York
|
-$20.5M |
AMLX Hedge Fund Activity: Q1 2024 in Review
143 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2024, worth a combined $141M — down 85% from $929M a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of AMLX and 25 opened new positions — a net loss of 35 holders — while 48 trimmed existing stakes and 56 added.
The largest buyer was Goldman Sachs, adding an estimated $22.1M. The largest seller was Morgan Stanley, cutting an estimated $47M.
- 143 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2024, down from 178 in Q4 2023.
- Funds reported $141M of Amylyx Pharmaceuticals stock for Q1 2024, down 85% quarter-over-quarter.
- 25 funds opened new Amylyx Pharmaceuticals positions in Q1 2024 and 60 closed out, a net change of -35 holders.
- The largest Amylyx Pharmaceuticals buyer in Q1 2024 was Goldman Sachs, an estimated $22.1M added.
- The largest Amylyx Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $47M sold.
Based on aggregated 13F filings for Q1 2024.